Fig. 6

IRF8 expression is reduced during breast and pancreatic cancer. a IRF8 measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-B6 tumor-bearing mice and tumor-free controls; n = 7/group. Data are representative of three independent experiments. b RT-qPCR analysis of BM GMPs, MDPs, and CDPs sorted from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-free controls for IRF8 target genes, four samples consisting of two mice each were analyzed per group. c pSTAT3 measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-B6 tumor-bearing mice and tumor-free controls; n = 6. Data are representative of two independent experiments. d IRF8 expression in total BM from BC and PDAC patients relative to healthy controls; n = 10/group. Data are from BC cohort 1 and PDAC cohort 1. e Correlation between BM pre-DCs and BM IRF8 expression in BC and PDAC patients. Data are from BC cohort 1 and PDAC cohort 1; n = 20. f IRF8 expression in blood pre-DCs from PDAC patients relative to healthy controls; healthy controls n = 10, PDAC n = 43. Data are from PDAC cohort 2. g Correlation between blood pre-DCs and blood pre-DC IRF8 expression in PDAC patients; n = 43. Data are from PDAC cohort 2. h Kaplan–Meier estimate of recurrence free survival and overall survival of patients +/− median blood pre-DCs IRF8 expression. Log-rank (Mantel–Cox) p value is denoted for differences in recurrence-free survival and overall survival. Data are from PDAC cohort 2. Spearman’s correlation (r², correlation coefficient). End stage for each model is defined in the Methods. Error bars represent mean +/− s.e.m or box plot; *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-sided Student’s t test